Urovant Sciences has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO). The company intends to price its 10 million shares in the range of $14 to $16 a piece, with an overallotment option for an additional 1.5 million shares. At the maximum price, the entire offering is valued up to $184.0 million. The company intends to list its shares on the Nasdaq under the symbol UROV.
The underwriters for this offering are JPMorgan, Jefferies, and Cowen.
This is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions. Its lead product candidate, vibegron, is an oral, once-daily, small molecule beta-3 agonist.
The company is currently evaluating vibegron in a 1,400-patient, international pivotal Phase 3 EMPOWUR trial for the treatment of overactive bladder (OAB). Management expects to report top-line results from this clinical trial in the first or second quarter of 2019, and if these results are positive, the company plans to submit a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) by early 2020.
Urovant detailed how it plans to use the net proceeds from this offering:
- Approximately $38.0 million to $42.0 million to complete our international Phase 3 EMPOWUR trial for vibegron in patients with OAB;
- Approximately $22.0 million to $26.0 million to advance through completion of site activation and initiation of patient enrollment both our planned Phase 3 clinical trial for vibegron for the treatment of OAB in men with BPH and our planned Phase 2a clinical trial for vibegron in patients with IBS-associated pain;
- Approximately $4.0 million to $7.0 million to advance through completion of site activation and initiation of patient enrollment our planned Phase 2a clinical trial for hMaxi-K for the treatment of OAB in patients who have not responded to oral pharmacological therapies; and
- The remainder to fund working capital, commercial readiness and general corporate purposes, which may include research and development of vibegron for other indications.
24/7 Wall St.Find a Qualified Financial Advisor (Sponsor)
Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes. Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you’re ready to be matched with local advisors that can help you achieve your financial goals, get started now.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
